Third generation of patents for the Bactiguard technology will be granted
Bactiguard has been informed that the European Patent Office (EPO) intends to grant a European patent for Bactiguard’s infection prevention technology. The new patent, which is the third generation, will provide extensive worldwide protection for the Bactiguard technology until 2039.
- We are very pleased that the EPO has confirmed that the new generation of patents will be granted. This will further strengthen and extend the worldwide protection for the versatile Bactiguard technology and make it even more attractive for existing and new license partners, says Anders Göransson, CEO.
For more than 30 years Bactiguard’s unique technology, based on a thin noble metal alloy coating, has been developed and applied to medical devices for both short- and long-term use. In 1994 urinary catheters with Bactiguard’s coating were approved by the FDA in the USA and have since then become market leading in the USA and Japan through our partnership with BD (Becton, Dickinson and Company). In 2019, Bactiguard initiated a global partnership with Zimmer Biomet and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched. In February 2022, the Zimmer Biomet partnership was expanded to cover most of their product portfolio.Our most recent development partnership is with Dentsply Sirona in the dental field.
The Bactiguard technology can be used in most areas where there is a need for infection prevention and tissue-friendly properties and is based on a valuable recipe, a well-kept trade secret. It is also protected by patents. The current patent, the second generation, is in force in the USA until 2027 and until 2029 in other countries. The application for the third generation of patents was submitted in 2019 and the EPO have now confirmed that they intend to grant a European patent, valid until 2039.
For more information, please contact:
Anders Göransson, CEO, +46 8 440 58 80
About BactiguardBactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with the Bactiguard technology are market leading in the USA and Japan through our licensing partner BD, and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue friendly.
Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about Bactiguard www.bactiguard.com